VMT-α-NET

VMT-α-NET is a clinical-stage targeted radiopharmaceutical therapy designed for the treatment of neuroendocrine tumors (NETs) that express somatostatin receptor subtype 2 (SSTR2). The drug consists of a peptide that binds specifically to SSTR2 and is conjugated with the alpha-emitting radionuclide lead-212 (^212Pb), enabling targeted delivery of cytotoxic radiation to tumor cells. This approach leverages both the specificity of peptide-receptor targeting and the potent cell-killing effects of alpha-particle radiation. VMT-α-NET is being developed primarily for patients with unresectable or metastatic NETs—including gastrointestinal neuroendocrine tumors and pheochromocytoma/paraganglioma—who have shown disease progression and often have limited treatment options. The drug has demonstrated favorable safety in early-phase trials, with encouraging signals for anti-tumor activity[1][3][4][6][7].

Other names

VMT-alpha-NET[212Pb]VMT-α-NET